Email ID
Password
Scrip   
Novartis to invest up to $2.3 billion in blood disorders, cancer and vaccines
25 November 2009
Simon Varcoe

Novartis could pay the US firm Incyte up to $1.3 billion for the ex-US rights to its Janus kinase (JAK) inhibitor INCB18424 and the global rights to its mesenchymal-epithelial transition factor kinase (cMET) inhibitor INCB28060. Both products are orally targeted investigational treatments for a range...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36